Advanced Therapeutic Strategies for Hormone-Dependent Cancers
A special issue of Biomolecules (ISSN 2218-273X).
Deadline for manuscript submissions: 31 March 2026 | Viewed by 36
Special Issue Editor
Interests: biochemistry; GPCR signaling; molecular pharmacology; molecular mechanisms of pharmacological action; cell biology; cancer research; drug design
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are pleased to invite you to contribute to a Special Issue of Biomolecules titled “Advanced Therapeutic Strategies for Hormone-Dependent Cancers”. Hormone-dependent cancers, such as those affecting the breast, prostate, ovaries, and endometrium, continue to pose serious challenges to global health because of their high morbidity and mortality rates. In spite of advances in endocrine treatments, the problems of treatment resistance and disease recurrence remain. The improvement of patient outcomes for these disorders requires both an improved knowledge of the molecular mechanisms underlying drug resistance, together with the development of new therapeutic approaches. This Special Issue will focus on current developments in treatment strategies for hormone-dependent cancers and will include both preclinical and clinical study results.
The aim of this Special Issue is to investigate cutting-edge therapy approaches for hormone-dependent malignancies, including combination therapies, new drug development, and treatment resistance mechanisms. It will encompass a wide range of strategies, including precision medical approaches, tailored medications, and immunotherapies, to overcome the current limitations on treatment effectiveness. Since Biomolecules focuses on molecular biology and biochemistry in relation to disease mechanisms, drug discovery, and therapeutic options, the topic is ideally suited to the journal's scope. The Special Issue will feature research that contributes to the development of more effective, personalized treatments for these cancers, potentially transforming current therapeutic paradigms. We aim to publish at least 10 articles in this Special Issue, and it may be printed in book form if this number is reached. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- Novel drug discovery and repurposing for hormone-dependent cancers;
- Mechanisms of resistance to endocrine therapies;
- Development of combination therapies involving endocrine agents and immunotherapy;
- Advances in biomarkers for therapy response and patient stratification;
- Preclinical studies on emerging therapeutic agents;
- Systems biology and computational approaches in the design of hormone-targeted therapies;
- Innovative therapeutic strategies to overcome therapeutic resistance in hormone-driven cancers.
We look forward to receiving your contributions.
Dr. Athanasios A. Panagiotopoulos
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hormone-dependent cancers
- endocrine therapy resistance
- targeted therapy
- combination treatment strategies
- cancer biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
